| 16/10/25 | 07:00:09 | 16 Oct 2025 | | Appointments: Interim CEO and senior board advisor |
| 08/10/25 | 07:00:10 | 8 Oct 2025 | | Strategy Update |
| 29/09/25 | 07:00:18 | 29 Sept 2025 | | Presentation of Data on Glioblastoma |
| 12/09/25 | 07:00:18 | 12 Sept 2025 | | Board Changes |
| 09/09/25 | 07:01:00 | 9 Sept 2025 | | Interim Results |
| 09/09/25 | 07:00:17 | 9 Sept 2025 | | Change of Adviser |
| 05/09/25 | 14:58:52 | 5 Sept 2025 | | Notice of Results |
| 20/08/25 | 07:00:03 | 20 Aug 2025 | | ANGLE announces collaboration with Myriad Genetics |
| 08/07/25 | 07:00:12 | 8 Jul 2025 | | PARSORTIX ENABLES STUDY OF CANCER PROGRESSION |
| 30/06/25 | 17:50:10 | 30 Jun 2025 | | Result of 2025 Annual General Meeting |
| 17/06/25 | 07:00:12 | 17 Jun 2025 | | EACR 2025: Innovation in AR expression profiling |
| 17/06/25 | 07:00:10 | 17 Jun 2025 | | EACR 2025: Data demonstrating DNA dual analysis |
| 10/06/25 | 07:00:14 | 10 Jun 2025 | | Novel discoveries into the biology of cancer |
| 09/06/25 | 07:00:10 | 9 Jun 2025 | | POSTING OF ANNUAL REPORT AND NOTICE OF AGM |
| 06/06/25 | 07:00:12 | 6 Jun 2025 | | Board Changes |
| 28/05/25 | 07:00:05 | 28 May 2025 | | Preliminary Results |
| 23/05/25 | 07:00:09 | 23 May 2025 | | Notice of Results |
| 28/04/25 | 07:00:09 | 28 Apr 2025 | | RESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME |
| 21/03/25 | 07:00:10 | 21 Mar 2025 | | Issue of LTIP Options and Share Options |
| 21/03/25 | 07:00:08 | 21 Mar 2025 | | Results of Eisai Phase 2 pilot study |
| 06/02/25 | 07:00:07 | 6 Feb 2025 | | Novel findings using Parsortix |
| 29/01/25 | 07:00:04 | 29 Jan 2025 | | Analysis of CTC-DNA and ctDNA using Illumina assay |
| 24/01/25 | 10:05:00 | 24 Jan 2025 | | Parsortix used in research paper from ETH Zurich |
| 23/01/25 | 07:00:06 | 23 Jan 2025 | | Trading Update |
| 13/12/24 | 08:43:54 | 13 Dec 2024 | | HER2 presentation at SABCS |
| 15/11/24 | 07:00:06 | 15 Nov 2024 | | Research on HER2 assay kit showcased at AACR |
| 15/11/24 | 07:00:06 | 15 Nov 2024 | | Parsortix based PD-L1 assay showcased at AACR |
| 13/11/24 | 07:00:10 | 13 Nov 2024 | | ANGLE presents two posters at EACR |
| 11/11/24 | 07:00:10 | 11 Nov 2024 | | Parsortix enriched CTC & ctDNA in NSCLC patients |
| 17/10/24 | 07:00:09 | 17 Oct 2024 | | Publication demonstrates CTC profiling potential |
| 26/09/24 | 07:01:01 | 26 Sept 2024 | | 100th publication supporting Parsortix system use |
| 26/09/24 | 07:00:13 | 26 Sept 2024 | | Half-year Report |
| 23/09/24 | 07:00:07 | 23 Sept 2024 | | Exclusive agreement for DNA NGS panel |
| 19/09/24 | 07:00:11 | 19 Sept 2024 | | Agreement with Recursion Pharmaceuticals |
| 17/09/24 | 07:00:11 | 17 Sept 2024 | | Notice of Interim Results and Webcast |
| 22/08/24 | 07:00:15 | 22 Aug 2024 | | Data supporting FDA approval published in Journal |
| 01/08/24 | 07:00:20 | 1 Aug 2024 | | Independent Parsortix study |
| 18/07/24 | 10:08:22 | 18 Jul 2024 | | Standard form for notification of major holdings |
| 12/07/24 | 15:38:33 | 12 Jul 2024 | | Standard form for notification of major holdings |
| 11/07/24 | 15:07:44 | 11 Jul 2024 | | Result of 2024 Annual General Meeting |
| 21/06/24 | 07:00:12 | 21 Jun 2024 | | Result of open offer |
| 18/06/24 | 14:41:25 | 18 Jun 2024 | | Posting of 2023 Annual Report & Notice of the AGM |
| 11/06/24 | 07:00:10 | 11 Jun 2024 | | Parsortix and assays being showcased at EACR 2024 |
| 06/06/24 | 16:37:51 | 6 Jun 2024 | | Publication of Circular |
| 05/06/24 | 16:04:55 | 5 Jun 2024 | | Results of placing and subscription |
| 05/06/24 | 07:00:11 | 5 Jun 2024 | | Proposed Placing, Subscription and Open Offer |
| 05/06/24 | 07:00:10 | 5 Jun 2024 | | Preliminary Results |
| 16/05/24 | 07:00:13 | 16 May 2024 | | Study of ovarian cancer CTCs using Parsortix |
| 03/05/24 | 07:00:09 | 3 May 2024 | | New commercial agreement with large pharma |
| 24/04/24 | 07:00:10 | 24 Apr 2024 | | New commercial agreement with AstraZeneca |
